Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;95(12):2111-8.
doi: 10.3324/haematol.2010.028829. Epub 2010 Sep 7.

Nuclear factor-kappaB inducing kinase is required for graft-versus-host disease

Affiliations

Nuclear factor-kappaB inducing kinase is required for graft-versus-host disease

Carmen Sánchez-Valdepeñas et al. Haematologica. 2010 Dec.

Abstract

Background: Donor T lymphocytes are directly responsible for graft-versus-host disease. Molecules important in T-cell function may, therefore, be appropriate targets for graft-versus-host disease therapy and/or prophylaxis. Here we analyzed whether nuclear factor-κ B inducing kinase might have a role in graft-versus-host disease.

Design and methods: We studied the expression of nuclear factor-κ B inducing kinase in human samples from patients with graft-versus-host disease. We also explored the effect of nuclear factor-κ B inducing kinase in a murine model of graft-versus-host disease using donor cells from aly/aly mice (deficient in nuclear factor-κ B inducing kinase) and C57BL/6 mice (control).

Results: We detected expression of nuclear factor-κ B inducing kinase in T-lymphocytes in the pathological lesions of patients with acute graft-versus-host disease. Mice transplanted with aly/aly T lymphocytes did not develop graft-versus-host disease at all, while mice receiving C57BL/6 cells died of a lethal form of the disease. Deficiency of nuclear factor-κ B inducing kinase did not affect the engrafting ability of donor T cells, but severely impaired their expansion capacity early after transplantation, and aly/aly T cells showed a higher proportion of apoptosis than did C57BL/6 T cells. Effector T lymphocytes were the T-cell subset most affected by nuclear factor-κ B inducing kinase deficiency. We also detected lower amounts of inflammatory cytokines in the serum of mice receiving aly/aly T cells than in the serum of mice receiving C57BL/6 T cells.

Conclusions: Our results show that nuclear factor-κ B inducing kinase has a role in graft-versus-host disease by maintaining the viability of activated alloreactive T lymphocytes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Expression of NIK in human graft-versus-host disease (GVHD). (A) Skin and (B) colon biopsies of a patient with acute GVHD. T lymphocytes positive for NIK expression were identified by immunohistochemical staining with an anti-NIK monoclonal antibody. Positive T lymphocytes are recognized by a dark-brown cytoplasmic and nucleic stain. (C) A biospy taken from a patient negative forGVHD showing no positive signal within the T lymphocytes, but only a slight background stain. The darkest spots correspond to melanophagocytes.
Figure 2.
Figure 2.
GVHD across the major histocompatibility complex barrier did not develop with NIK-deficient T lymphocytes. Survival analysis of Balb/c mice transplanted with C57BL/6 or aly/aly cells (107 marrow cells plus splenocytes containing 2×106 CD8 cells). Results shown are from two independent experiments, with a total of 12 mice per group.
Figure 3.
Figure 3.
T-cell expansion early during acute GVHD is impaired in aly/aly mice. (A) Purified T lymphocytes from spleens (Pre) were depleted of CD44-positive cells by immunomagnetic methods. The purity of depleted cells was assessed by flow cytometry (Post). (B) Donor T lymphocyte numbers recovered from the spleens of Balb/c mice transplanted with T cells (as explained in A) from C57BL/6 (solid bars) or aly/aly (open bars) mice. Note that Y labels are different at each time point analyzed. Representative of three experiments. (C) Total numbers of donor naïve (N), central memory (CM) and effector (E) T lymphocytes recovered from the spleens of Balb/c mice transplanted 120 h before with T cells (as explained in A) from aly/aly (open bars) or C57BL/6 (solid squares) mice. Each subpopulation is shown in more detail below. Results show the mean ± standard error, three mice per group. *P<0.05. **P<0.01.
Figure 4.
Figure 4.
T-cell proliferation is maintained but apoptosis is enhanced early during acute GVHD in aly/aly mice. (A) Dilution of CFSE in donor T lymphocytes recovered from the spleens of Balb/c mice transplanted with purified T cells from aly/aly (top) or C57BL/6 (bottom) mice. Histograms represent CFSE intensity gated on donor cells. Representative of a single animal per group. (B) Proportions of annexin V-positive donor T lymphocytes recovered from the spleens of Balb/c mice transplanted with T cells from C57BL/6 (solid bars) or aly/aly (open bars) mice. Results shown are from two independent experiments, mean ± standard error, six mice per group per time point. *P<0.05.
Figure 5.
Figure 5.
Th1 cytokine production is severely impaired in mice transplanted with aly/aly T lymphocytes. The levels of circulating IL-2, IL-12, IF-γ and TNF-α in Balb/c mice transplanted with C57BL/6 (black circles) or aly/aly (white circles) purified T lymphocytes. Three mice per time-point per group. Results show the mean ± standard error. *P<0.05.

Similar articles

Cited by

References

    1. Thomas ED. Bone marrow transplantation: a review. Semin Hematol. 1999;36(4 Suppl 7):95–103. - PubMed
    1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61. - PMC - PubMed
    1. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340–52. - PubMed
    1. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109(10):4119–26. - PMC - PubMed
    1. Ferrara JLM, Cooke KR, Teshima T. The pathophysiology of graft-vs-host disease. In: Ferrara J, Cooke K, Deeg J, editors. Graft-vs-Host Disease. 3rd edition. New York: Marcel Dekker; 2005. pp. 1–34.

Publication types

MeSH terms

Substances